If You Get Seriously Ill, How Much Cheaper Is Self-Pay Care in China?

— Cross-Border Retirement Ledger, Part Three

The previous article looked at a relatively straightforward question: how much might an ordinary year of medical care cost in China without health insurance?

For a 70-year-old retiree who mainly uses public hospitals and does not require expensive long-term medications, six doctor visits, two rounds of chronic-disease monitoring, plus an ECG, CT scan, MRI, and colonoscopy came to roughly RMB 4,887 based on the prices we examined. Even if we raise the annual routine-care budget to RMB 10,000, there appears to be a meaningful cushion.

But routine medical care is rarely what people fear most.

What happens if you have a heart attack and need a coronary stent? What if you develop cancer and need surgery, chemotherapy, or targeted therapy? What if you suffer a stroke or hip fracture and require hospitalization and rehabilitation? And what if your condition becomes serious enough to require intensive care?

Without Chinese health insurance, could a retiree still pay for all of this out of retirement income and savings?

That is the real stress test for a self-funded retirement in China.

To make the question more concrete, instead of asking only how much a serious illness costs in China, let us consider a retiree with $1,500 a month in stable retirement income and $200,000 in financial assets.

This person is not wealthy, but neither is he without resources. He represents exactly the kind of retiree this series is intended to examine: someone with Social Security and meaningful retirement savings, but not so much wealth that the cost of health care and long-term care no longer matters.

In our earlier retirement model, we set aside $60,000 for a major medical event. Using our planning exchange rate of RMB 6.7 to the dollar, that equals roughly RMB 400,000.

The question now is whether RMB 400,000 is a tight medical reserve—or whether it already contains a substantial margin of safety.

A coronary stent: What does RMB 44,000 really mean?

Start with one of the medical emergencies older adults fear most: cardiovascular disease.

In 2026, China’s National Healthcare Security Administration published a real-world study covering more than 90,000 patients at eight large hospitals across the country. Before centralized procurement reforms, the average total hospitalization cost for percutaneous coronary intervention, or PCI, was close to RMB 60,000. After the reforms, it fell to roughly RMB 44,000. The cost of coronary stents themselves also dropped dramatically.

For someone covered by Chinese health insurance, RMB 44,000 would not necessarily be the final amount paid out of pocket. But our hypothetical retiree has no Chinese health insurance, so we assume that the full cost must be paid personally.

At RMB 6.7 to the dollar, RMB 44,000 is about $6,600.

For someone with $200,000 in financial assets, that represents roughly 3.3% of those assets.

That percentage may be more useful than simply hearing that the hospital bill is RMB 44,000. A serious cardiovascular event is certainly not trivial, but a medical bill equal to a little more than 3% of financial assets is unlikely, by itself, to destroy the retirement plan of someone with $200,000 in savings and a stable monthly income.

This is where China’s lower medical prices become financially important.

Having no insurance means paying the entire bill. But if the bill itself represents only a few percentage points of a retiree’s assets, “self-pay” does not carry the same financial meaning that being uninsured typically carries in the United States.

With cancer, duration may matter more than surgery

Cancer is far more complicated.

China’s National Healthcare Security Administration has published several real treatment cases. One breast cancer patient received 12 rounds of chemotherapy over nine months, with total costs of about RMB 39,300. A 74-year-old colorectal cancer patient underwent 14 targeted-therapy treatments costing about RMB 114,800. A 77-year-old stomach cancer patient received 10 immunotherapy treatments costing about RMB 42,000. Another patient with a malignant brain tumor underwent surgery, targeted therapy, and chemotherapy at a total cost of approximately RMB 133,200.

These figures should not be interpreted as average cancer-treatment costs in China. They are individual cases involving different diseases and treatment paths. But they do give us some idea of the range in which major treatment expenses can fall.

For a retiree with $200,000 in financial assets, RMB 114,800 is about $17,100, or 8.6% of financial assets. RMB 133,200 is approximately $19,900, or about 10%.

In other words, even without Chinese health insurance, neither of these cases—both involving substantial cancer treatment—would have consumed one-fifth of this retiree’s financial assets.

That does not mean cancer should be underestimated. The greater danger may not be the cost of a single surgery, but how long treatment continues. Some cancers can be treated surgically and then monitored. Others require prolonged chemotherapy, targeted drugs, or immunotherapy, and newer medications can move the cost into an entirely different range.

China’s National Healthcare Security Administration has described one expensive targeted cancer drug that, before insurance coverage, cost nearly RMB 10,000 per box, with some patients needing roughly four boxes a month. The annual financial burden could exceed RMB 210,000.

At our planning exchange rate, that is more than $30,000 a year. Two years of treatment at that level would begin to approach the $60,000 major-illness reserve in our model.

Cancer therefore tests something more important than the price of an operation. It tests whether treatment becomes a financial obligation lasting several years.

Stroke and hip fracture: The next bill may begin after the hospital bill ends

Stroke and hip fracture create a different kind of risk. Their largest financial consequences may not come from the acute hospital treatment itself, but from whether the patient can regain independent function afterward.

A Chinese study covering 16,827 rehabilitation inpatients from 2018 through 2024 found that the average hospitalization cost for stroke rehabilitation in 2024 was about RMB 11,200. That is not the total cost of a stroke from emergency treatment through recovery, but it illustrates that rehabilitation itself creates an additional layer of expense.

Hip fractures present a similar problem. Surgery, internal fixation, or joint replacement is only the beginning. What may matter more for an older person is what happens over the following months: Can the patient walk again? Bathe and dress without assistance? Use the bathroom independently? Continue living alone?

For that reason, there is little value in forcing a single “average Chinese hip-fracture cost” into this article simply to make five medical conditions fit neatly into the same format.

For retirement planning, the more important point is that some of the largest financial consequences of serious illness do not appear on the hospital bill at all. They appear in the disability left behind.

If a stroke costs tens of thousands of yuan to treat but leaves someone dependent on help for the next ten years, the expense that eventually transforms the retirement balance sheet is no longer primarily medical care.

It is long-term care.

That is the bill we will examine next.

ICU: Where the RMB 400,000 reserve faces a real stress test

If there is one setting where medical expenses can quickly move beyond an ordinary health-care budget, it is the intensive care unit.

There is no meaningful single daily price for ICU care because different patients require very different levels of treatment. China’s Health Times has reported a real case at a tertiary hospital in a second-tier city where ICU expenses approached RMB 4,000 per day. Critical-care specialists interviewed for the report also noted that ventilators, renal replacement therapy, ECMO, and other forms of advanced life support can push costs substantially higher.

Using RMB 4,000 per day only as a reference point, ten days would cost roughly RMB 40,000 and 30 days about RMB 120,000.

RMB 120,000 is approximately $17,900 at our planning exchange rate, or about 9% of a $200,000 portfolio. Even that remains well below our $60,000 major-illness reserve.

But ICU care is precisely the kind of medical expense that should not be projected from a simple average. Severe infection, multiple-organ failure, dialysis, ECMO, and expensive medications can all drive costs much higher.

RMB 400,000 therefore should not be interpreted as “enough to pay for 100 days in an ICU.” What it tells us is that, compared with a number of serious-illness and critical-care cases we can document, RMB 400,000 already sits well above many observed treatment costs. Extreme cases, however, can still exceed it.

If U.S. health care costs so much more, why not simply compare hospital bills?

Now consider the United States.

If we compare only the total prices charged for medical treatment, China’s advantage can appear enormous. But that is not a fair comparison for a 70-year-old American retiree, because that person will typically already have Medicare.

That changes the financial calculation.

In 2026, the Original Medicare Part A inpatient deductible is $1,736. Within a benefit period, after that deductible has been met, there is no daily hospital coinsurance for the first 60 days. Physician services, outpatient treatment, some chemotherapy, and many diagnostic services generally fall under Part B. After the annual deductible, the patient typically pays about 20% of the Medicare-approved amount. Prescription drugs may be covered through Part D, with additional cost-sharing depending on the plan.

A medical episode that generates tens of thousands of dollars—or substantially more—in total U.S. health-care costs therefore does not mean that the retiree must withdraw the same amount from a $200,000 portfolio.

That is one of Medicare’s most important functions: it transfers a substantial portion of major medical risk away from the retiree’s personal assets and into the insurance system.

We therefore cannot look at a roughly $6,600 average hospitalization cost for coronary intervention in China, observe that the total cost of comparable U.S. treatment is much higher, and conclude that the Chinese retiree’s personal financial risk must be lower by the same proportion.

The self-paying retiree in China is responsible for the entire cash bill. The Medicare beneficiary in the United States is responsible only for the portion assigned to the patient under Medicare’s coverage rules. Once serious illness enters the picture, China’s advantage over the United States is therefore less dramatic than it is for routine doctor visits, laboratory tests, CT scans, or common medications.

But we should not go too far in the other direction either. Medicare does not reduce personal financial risk to zero. Part A has deductibles, Part B generally has coinsurance, Part D involves premiums and drug cost-sharing, and Original Medicare itself does not have a single annual out-of-pocket maximum.

That is why it would also be misleading to say, “With Medicare, the most a retiree can lose from one serious illness is X dollars.” No single national number applies to every retiree, treatment path, and medical condition.

How much serious illness can $200,000 withstand?

We can now return to the question with which we began.

Suppose our retiree has $1,500 a month in stable retirement income and $200,000 in financial assets. If this person lives in China without Chinese health insurance, the serious-illness cases we have examined produce a clearer picture of the potential impact on those assets.

An average coronary intervention hospitalization of about $6,600 would consume roughly 3.3% of the portfolio. The colorectal cancer targeted-therapy case, at about $17,100, would consume 8.6%. The malignant brain-tumor case, at approximately $19,900, would consume about 10%. A 30-day ICU scenario using RMB 4,000 per day would cost about $17,900, or roughly 9%.

Our deliberately conservative $60,000 major-illness reserve, by comparison, represents 30% of a $200,000 portfolio.

That gives the $60,000 assumption a much clearer meaning. It is not a claim that treating a serious illness in China typically costs $60,000. In fact, many of the documented cases we have examined cost substantially less.

We continue to reserve $60,000 because retirement planning should not be built around the average case alone. Treatment may continue for years. Cancer can recur. Expensive medications may be required for long periods. ICU care may involve complex life support. And a person can suffer more than one major illness in old age.

The $60,000 reserve is therefore better understood as a deliberately elevated line of defense. For someone with $200,000 in financial assets, even using the entire reserve would leave $140,000. In many of the serious-illness cases we have examined, only a portion of that reserve would have been needed.

None of this proves that self-paying in China is necessarily safer than relying on Medicare in the United States. It demonstrates something more specific: when the underlying price of medical care is low enough, “having no insurance” and “being unable to afford medical risk” are not necessarily the same thing.

The United States uses a different mechanism. Medical care is expensive, so retirees continuously pay for Medicare coverage and transfer a substantial portion of serious medical risk to the insurance system. A self-paying retiree in China does not have that insurance layer. Instead, the retiree relies on lower medical prices, stable retirement income, and personal assets to absorb the risk.

The real comparison in a cross-border retirement ledger, then, is not simply whether China offers health insurance or whether the United States offers Medicare. It is what happens to the same person—with perhaps $1,500 to $2,500 in monthly retirement income and $100,000 to $300,000 in financial assets—when a serious illness occurs under each system. How much of the risk ultimately remains with the retiree, and how much of the retirement portfolio is lost?

For major illness, the answer is beginning to come into focus. China’s self-pay advantage is that the total cost of many serious treatments remains within a range that a moderate retirement portfolio may be able to absorb. Medicare’s advantage is that even when the total cost of U.S. medical care is extremely high, the retiree does not have to pay the entire bill.

Both mechanisms can reduce the financial threat of serious illness. They simply do it in very different ways.

The balance changes again, however, if a person survives the illness but never regains the ability to live independently. If five or ten years of daily assistance are required, the question is no longer primarily how much a hospital charges.

It is how long the retirement assets can pay for care.

This article is part of Chinese Voices’ “Cross-Border Retirement Ledger” series. Rather than asking which country is “better” for retirement, the series looks at health care, long-term care, income, and assets to examine the financial risks of cross-border retirement—one calculation at a time.

By Voice in Between